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factors was admitted to the emergency room with new-onset
dyspnoea and fever. The symptoms started 1 day after
receiving the first of two mRNA-1273 (Moderna, Cambridge,
MA, USA) COVID-19 vaccinations. She had no other priorFigure 1 Multimodality imaging using ventriculography, Echoc
cardiomyopathy after COVID-19 mRNA vaccination.
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coronavirus 2 polymerase chain reaction test was negative.
Laboratory tests revealed normal results for creatinine,
creatine kinase, and creatine kinase MB (myocardial type).
High-sensitivity troponin T was elevated at 320 ng/Lardiography and cardiac magnetic resonance of Takotsubo
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natriuretic peptide was highly elevated at 10,180 pg/mL
(normal: ,284 pg/mL). C-reactive protein was elevated, but
the leucocytes were within the normal range at 8.44 g/L
(reference interval [RI]: 3.00–10.5 g/L). Urine and blood
cultures were negative. Computed tomography scan of the
chest revealed no pulmonary embolism but did show signs
of heart failure. An electrocardiogram showed negative
T waves over the inferior/anterior leads. Invasive coronary
angiography ruled out coronary artery disease, but the
ventriculogram (Figure) showed mid-ventricular to apical
ballooning (asterisk) with preserved basal contraction
(blues arrows) and a moderately impaired left ventricular
ejection fraction of 40%. Apical ballooning was confirmed
by echocardiography and cardiac magnetic resonance im-
aging (CMR). CMR tissue characterisation further depicted
extensive oedema in the mid-ventricular/apical segments
(i.e., T2-weighted imaging in the myocardium vs skeletal
muscle with a signal intensity ratio of .2.0), elevated T2
mapping at 56 ms (RI: 42–50 ms), elevated T1 mapping at
1,158 ms (RI: 903–1,059 ms), and the extracellular volume
fraction was elevated at 35% (RI: 2564%). There was no late
gadolinium enhancement suggesting peri-/myocarditis
and no pleural or pericardial effusion. As there were no
other stressors that could be determined to be underlying
the midventricular/apical oedema and ballooning, thePlease cite this article in press as: Boscolo Berto M, et al. Takots
Heart, Lung and Circulation (2021), https://doi.org/10.1016/j.hlmost probable diagnosis of COVID-19 vaccine-induced
Takotsubo cardiomyopathy (TCM) was made. Although
myocarditis is a possible differential diagnosis after
COVID-19 vaccination [1], the clinical and investigative
features of this case were strongly suggestive of TCM.
There have been rare reports of TCM after influenza
vaccination [2,3], with an underlying pathophysiology of
systemic inflammatory stress reaction after vaccination
with a sympathovagal imbalance towards adrenergic pre-
dominance [4]. TCM confirmed by CMR after a COVID-19
vaccination has not yet been reported and may be consid-
ered as a differential diagnosis besides myocarditis in this
clinical setting.
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